Appendix 1.

Complete results of literature review including all publications that presented results of serum and CSF NMDAR IgG autoantibody testing in patients with definite anti-NMDAR encephalitis.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Reference / Testing Location (SCImago Rank of 271) | Paired samples (n) | Age (median [range]) | M:F | NMDAR antibody testing | |
| Serum +: CSF + | Technique / Test Site |
| Gresa-Arribas et al., 20141  University of Pennsylvania (14) | 250 | unknown | unknown | 232:250 | 2 / R |
| Wang et al., 20152  Peking Union Medical College Hospital (166) | 43 | 23 [9 - 39] | 19:24 | 27:43 | 1 / L |
| Saito et al., 20173  Kanazawa University Hospital (192) | 37 | unknown | unknown | 17:37 | 1 / L |
| Aungsumart et al., 2019 4  Prasat Neurological Institute (NL) | 31 | 19 [IQR: 15 - 31] | 12:19 | 21:31 | 2 / L |
| Ding et al., 20185  Nanfang Hospital (158) | 24 | Mean: 40 (SD: 18) | 10:14 | 18:24 | 1 / L |
| Ge et al., 20166 | 20 | unknown | unknown | 20:20 | U / U |
| Erazo et al., 20167  University of Pennsylvania (14) | 13 | 6 [1 - 16] | 9:4 | 13:13 | U / R |
| Maat et al., 20138  Erasmus Medical Center (24) | 12:15 | 25 [5 – 56] | 2:13 | 9:12 (0) | 1 / R ★ |
| Mahadevan et al., 20169  NIMHANS (NL) | 11 | unknown | unknown | 11:11 | 1 / L |
| Liba et al., 201610 | 9 † | 13 [7 - 26] | 1:8 | 9:9 | 1 / U 🟁 |
| Ramirez et al., 201511  San Luis Potosi City Reference Hospitals (NL) | 8 | unknown | unknown | 8:8 | U / L |
| Holzer et al., 201312 | 7 | 22 [17 - 58] | 1:6 | 7:7 | U / U |
| Gao et al., 201413 | 7 | Female: [19 - 31], Male: 52 [47 - 58] | 2:5 | 6:7 | U / U |
| Candia et al., 201514 | 6 | [5 - 16] | 0:6 | 6:6 | U / U\* |
| Pruss et al., 201015 | 6 | 22.5 [18 - 31] | 0:6 | 5:6 | 2 / U 🟁 |
| Song et al., 201316 | 5:6 | unknown | unknown | 5:5 (0) | U / U 🟁 |
| Zhou et al., 201417 | 5 | unknown | unknown | 5:5 | U / U |
| Suhs et al., 201518  Hannover Medical School (NL) | 5:7 † | [23 - 57] | 0:7 | 4:5 (1) | 1 / L ★ |
| Zoccarato et al., 201719 | 4 | [7 - 27] | 3:1 | 4:4 | 1 / U |
| Kataoka et al., 201720  University of Pennsylvania (14) | 3 | 29 [18 - 46] | 1:2 | 3:3 | 2 / R ★ |
| Bashiri et al., 201721 | 3 | [10 mo - 5] | 0:3 | 3:3 | U / U 🟁 |
| Bastos et al., 201322 | 3 | [13 - 34] | 0:3 | 3:3 | U / U |
| Gastaldi et al., 201623  Oxford University Hospitals (68) | 3:5 | unknown | unknown | 3:3 | 2 / R ★ |
| Nosadini et al., 201324 | 3 | unknown | unknown | 3:3 | 1 / U |
| Su et al., 201525 | 3 | unknown | 2:1 | 3:3 | U / U 🟁 |
| Zandi et al., 201526  Oxford University Hospitals (68) | 5:8 | unknown | unknown | 5:5 (3) | 2 / R ★ |

Appendix 1 (continued)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Reference / Testing Location (SCImago Rank of 271) | Paired samples (n) | Age (median [range]) | M:F | NMDAR antibody testing | |
| Serum +: CSF + | Technique / Test Site |
|  |  |
| Wright et al., 2015 27 | 2 | 2 [2] | unknown | 2:2 | U / U |
| Sankhyan et al., 2015 28 | 2 | 6 [4 - 8] | 1:1 | 2:2 | U / U |
| Aung et al., 2015 29 | 2 | 23 [23 - 23] | 1:1 | 2:2 | U / U |
| Alexopoulos et al., 2018 30  Athens University Hospital (202) | 5:5 | 29 [9 mo, 58] | 0:2 | 3:3 (1) | 1 / L |
| Qin et al., 2017 31 | 2:4 | 36 [33 - 39] | 2:0 | 2:2 | U / U 🟁 |
| Qiu et al., 2018 32 | 2:4 | 49 [31 - 67] | 0:2 | 2:2 | U / U |
| Kitada et al., 2011 33 | 2 | 54 [38, 71] | 1:1 | 2:2 | 2 / U |
| Tuzun et al., 2015 34 | 2 | 63 [62 - 64] | 2:0 | 2:2 | U / U |
| Gaunt et al., 2017 35 | 1 | 7 mo | 0:1 | 1:1 | U / U |
| Crowe et al., 2014 36 | 1 | 16 mo | 0:1 | 1:1 | U / U |
| Bektas et al., 2013 37 | 1 | 19 mo | 0:1 | 1:1 | U / U 🟁 |
| Iyer et al., 2014 38 | 1 | 3 | 1:0 | 1:1 | U / U |
| Deiva et al., 2014 39 | 1 | 4 | 0:1 | 1:1 | U / U 🟁 |
| Barros et al., 2014 40  Oxford University Hospitals (68) | 1 | 7 | 1:0 | 1:1 | 2 / R |
| Lee et al., 2016 41 | 1 | 7 | 0:1 | 1:1 | U / U 🟁 |
| Tamma et al., 2011 42 | 1 | 7 | 1:0 | 1:1 | U / U |
| Mitani et al., 2013 43 | 1 | 8 | 1:0 | 1:1 | U / U 🟁 |
| Cai et al., 2018 44  Peking Union Medical College Hospital (166) | 1 | 9 | 0:1 | 1:1 | U / L 🟁 |
| Korenke et al., 2013 45 | 1 | 12 | 1:0 | 1:1 | U / U |
| Elango et al., 2016 46 | 1 | 13 | 0:1 | 1:1 | U / U |
| Babiker et al., 2015 47 | 1 | 15 | 0:1 | 1:1 | U / U |
| Kevere et al., 2015 48 | 1 | 15 | 0:1 | 1:1 | U / U |
| Rangseekajee et al., 2015 49 | 1 | 15 | 0:1 | 1:1 | U / U |
| Ubod et al., 2016 50 | 1 | 15 | 1:0 | 1:1 | U / U |
| Wang et al., 2016 51 | 1 | 15 | 0:1 | 1:1 | U / U 🟁 |
| Dasyam et al., 2014 52 | 1 | 17 | 0:1 | 1:1 | U / U |
| Nastase et al., 2012 53 | 1 | 18 | 0:1 | 1:1 | U / U |
| Pereira, et al. 2016 54 | 1 | 18 | 0:1 | 1:1 | U / U |

Appendix 1 (continued)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Reference / Testing Location (SCImago Rank of 271) | Paired samples (n) | Age (median [range]) | M:F | NMDAR antibody testing | |
| Serum +: CSF + | Technique / Test Site |
|  |  |
| Sousa et al., 2014 55 | 1 | 18 | 0:1 | 1:1 | U / U |
| Gutierrez-Zuniga et al., 2016 56 | 1 | 19 | 0:1 | 1:1 | U / U |
| Shimoyama et al., 2016 57 | 1 | 19 | 0:1 | 1:1 | U / U |
| Fontao et al., 2016 58 | 1 | 20 | 1:0 | 1:1 | U / U |
| Liang et al., 2016 59 | 1 | 20 | 0:1 | 1:1 | U / U |
| Wang et al., 2018 60 | 1 | 20 | 0:1 | 1:1 | U / U |
| Algra et al., 2014 61 | 1 | 21 | 0:1 | 1:1 | U / U |
| Barrozo et al., 2017 62 | 1 | 21 | 1:0 | 1:1 | U / U |
| Fauzi et al., 2017 63  Hospital Kuala Lumpur (NL) | 1 | 21 | 0:1 | 1:1 | 1 / L ★ |
| Salehi et al., 2018 64 | 1 | 21 | 0:1 | 1:1 | U / U |
| Tachibana et al., 2010 65 | 1 | 21 | 0:1 | 1:1 | 1 / U 🟁 |
| Vansia et al., 2016 66 | 1 | 22 | 0:1 | 1:1 | U / U |
| Amado-Rodriguez et al., 2018 67 | 1 | 23 | 0:1 | 1:1 | U / U 🟁 |
| Rehder et al., 2016 68 | 1 | 24 | 0:1 | 1:1 | U / U |
| Grewal et al., 2018 69 | 1 | 25 | 0:1 | 1:1 | U / U 🟁 |
| Anadani et al., 2014 70 | 1 | 26 | 1:0 | 1:1 | U / U |
| Shahani et al., 2014 71 | 1 | 26 | 0:1 | 1:1 | U / U |
| Shahbeigi et al., 2014 72 | 1:3 | 27 | 0:1 | 1:1 | U / U |
| Kaneko et al., 2015 73 | 1 | 28 | 0:1 | 1:1 | U / U |
| O'Donnell et al., 2017 74 | 1 | 28 | 1:0 | 1:1 | U / U |
| Li et al., 2018 75 | 1 | 29 | 0:1 | 1:1 | U / U 🟁 |
| Cesarini et al., 2018 76 | 1 | 30 | 0:1 | 1:1 | U / U |
| Hegen et al., 2016 77 | 1 | 31 | 0:1 | 1:1 | U / U 🟁 |
| Takahashi et al., 2013 78 | 1 | 31 | 0:1 | 1:1 | U / U |
| Yamamoto et al., 2013 79 | 1 | 31 | 0:1 | 1:1 | 1 / U |
| Bashir et al., 2017 80 | 1 | 32 | 0:1 | 1:1 | U / U |
| Chourasia et al., 2018 81 | 1 | 32 | 0:1 | 1:1 | U / U 🟁 |
| Munoz et al., 2015 82 | 1 | 32 | 0:1 | 1:1 | U / U |
| Park et al., 2018 83 | 1 | 33 | 0:1 | 1:1 | U / U |

Appendix 1 (continued)

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Reference / Testing Location (SCImago Rank of 271) | Paired samples (n) | Age (median [range]) | M:F | NMDAR antibody testing | |
| Serum +: CSF + | Technique / Test Site |
|  |  |
| Hur et al., 2015 84 | 1 | 36 | 0:1 | 1:1 | U : U 🟁 |
| Lineberry et al., 2013 85 | 1 | 38 | 0:1 | 1:1 | U / U |
| Thomas et al., 2012 86 | 1 | 39 | 0:1 | 1:1 | U / U |
| Wagner et al., 2018 87 | 1 | 40 | 1:0 | 1:1 | U / U |
| Hung et al., 2017 88 | 1 | 44 | 1:0 | 1:1 | U / U |
| Rojc et al., 2019 89 | 1 | 47 | 1:0 | 1:1 | U / U |
| Zoccarato et al., 2013 90 | 1 | 50 | 0:1 | 1:1 | U / U |
| Power et al., 2017 91 | 1 | 52 | 0:1 | 1:1 | U / U |
| Zhou et al., 2018 92  Euroimmune China (REF) | 1 | 54 | 1:0 | 1:1 | 1 / R |
| Guan et al., 2015 93  Peking Union Medical College Hospital (166) | 1 | 59 | 0:1 | 1:1 | 1 / L |
| Jeraiby et al., 2016 94 | 1 | 62 | 0:1 | 1:1 | U / U 🟁 |
| Chen et al., 2014 95 | 1 | unknown | 0:1 | 1:1 | U / U |
| Kelleher et al., 2015 96 | 1:4 | Female: 55, Male: Mean: 48 (SD: 16.3) | 3:1 | 1:1 | 1 / U |
| Kukreti et al., 2015 97 | 1 | unknown | 0:1 | 1:1 | U / U 🟁 |
| Mohammad et al., 2013 98 | 1 | unknown | 1:0 | 1:1 | U / U |
| Zhang et al., 2017 99 | 1 | 18 | 0:1 | 0:1 | U / U |
| Orengo et al., 2015 100  Mayo Clinic (7) / ARUP (REF) | 1 | 29 | 0:1 | 0:1 | 1 / R ★ |
| Berth et al., 2017 101 | 1 | 53 | 1:0 | 0:1 | U / U |
| Finke et al., 2014 102 | 1 | 67 | 1:0 | 0:1 | 1 / U 🟁 |
| Summary (Random Effects) |  | [7 mo - 71] | 97:222 | 532:612 |  |

With the authors / citation is listed the principal testing site / affiliated institution, and associated SCImago rank103 (where available). When relevant, the “n” for patients with paired samples indicates both the number of patients with paired CSF and serum samples (numerator), as a proportion of the total cases presented (denominator). The NMDAR autoantibody testing reports number of serum positive (numerator) compared to number of CSF positive (denominator) results. The number of patients who demonstrated positivity in serum but not CSF are included in parentheses (excluded from analyses). The median age and age range of patients presented in each study is listed unless otherwise stated. Time between CSF and serum testing, and severity of illness were not uniformly reported. No adverse events were reported secondary to blood draw or lumbar puncture. 1: Single modality testing; 2: Multimodal testing (≥2 modalities used); ARUP: Associated Regional University Pathologists, Inc.; CSF: Cerebrospinal fluid; L: Testing performed at a local/regional test site; NL: The test site was not listed in the available rankings; R: Testing performed at reference/research test site; REF: The testing center was a reference center; 🟁: Data clarification requested but not provided; ★: Data clarification requested and provided; †: Studies where more than one paired sample was obtained per patient.

Citations

1. Gresa-Arribas N, Titulaer MJ, Torrents A, et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. *The Lancet Neurology.* 2014;13(2):167-177.

2. Wang R, Guan HZ, Ren HT, Wang W, Hong Z, Zhou D. CSF findings in patients with anti-N-methyl-D-aspartate receptor-encephalitis. *Seizure.* 2015;29:137-142.

3. Saito M, Suzuki Y, Kikuchi Y, et al. Differences between auto-antibody titres in cerebrospinal fluids and sera of patients with anti-N-methyl-D receptor encephalitis. *Schizophrenia Bulletin.* 2017;43(Supplement 1):S67-S68.

4. Aungsumart S, Ha A, Apiwattanakul M. Abnormal level of consciousness predicts outcomes of patients with anti-NMDA encephalitis. *Journal of Clinical Neuroscience.* 2019;62:184-187.

5. Ding YW, Pan SY, Xie W, Shen HY, Wang HH. Elevated soluble Fas and FasL in cerebrospinal fluid and serum of patients with anti-N-methyl-D-aspartate receptor encephalitis. *Frontiers in Neurology.* 2018;9(OCT).

6. Ge J, Deng B, Zuo C, Chen X. Distinct cerebral 18F-FDG PET metabolic patterns in anti-nmethyl-D-aspartate receptor encephalitis patients with different trigger factors. *European Journal of Nuclear Medicine and Molecular Imaging.* 2016;43(1 Supplement 1):S63-S64.

7. Erazo R, Gonzalez J, Quintanilla C, et al. Subacute anti-N-methyl-D-aspartate receptor encephalitis. A serie of 13 paediatric cases. *Revista Chilena de Pediatria.* 2016;87(6):487-493.

8. Maat P, De Graaff E, Van Beveren NM, et al. Psychiatric phenomena as initial manifestation of encephalitis by anti-NMDAR antibodies. *Acta Neuropsychiatrica.* 2013;25(3):128-136.

9. Mahadevan A, Nagappa M, Bindu PS, et al. Utility of an advanced diagnostic facility for autoimmune neurological and neuropsychiatric disorders at neuromuscular lab at NIMHANS. *Annals of Indian Academy of Neurology.* 2016;19(6):S119.

10. Liba Z, Kayserova J, Elisak M, et al. Anti-N-methyl-D-aspartate receptor encephalitis: the clinical course in light of the chemokine and cytokine levels in cerebrospinal fluid. *J Neuroinflammation.* 2016;13(1):55.

11. Ramirez A, Bravo-Oro A, Rodriguez-Leyva I, Abud-Mendoza C. Methotrexate experience in eight pediatric patients with anti-N-methyl-D-aspartate-receptor encephalitis. *Neurology.* 2015;84(SUPPL. 14).

12. Holzer FJ, Rossetti AO, Heritier-Barras AC, et al. Antibody-mediated status epilepticus: A retrospective multicenter survey. *Epilepsia.* 2013;54(SUPPL. 6):120.

13. Gao L, Deng Q, Du H, Lin H, Li H. Application of predictive nursing intervention for patients with severe anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. *Brain Pathology.* 2014;24(SUPPL. 1):46.

14. Candia L, Brown R, Nowak A, et al. Acute pediatric inpatient rehabilitation in children with anti-NMDA receptor encephalitis. *Archives of Physical Medicine and Rehabilitation.* 2015;96(10):e80.

15. Pruss H, Dalmau J, Harms L, et al. Retrospective analysis of NMDA receptor antibodies in encephalitis of unknown origin. *Neurology.* 2010;75(19):1735-1739.

16. Song L, Liu AH. Anti-N-methyl-D-aspartic acid receptor encephalitis: clinical analysis of 7 cases. *National Medical Journal of China.* 2013;93(31):2508-2510.

17. Zhou X, Sun D, Feng L, et al. Ovarian teratoma associated with anti-N-methyl-D-aspartate receptor encephalitis: a report of 5 cases and review of the literature. *Zhonghua fu chan ke za zhi.* 2014;49(4):281-286.

18. Suhs KW, Wegner F, Skripuletz T, et al. Heterogeneity of clinical features and corresponding antibodies in seven patients with anti-NMDA receptor encephalitis. *Exp Ther Med.* 2015;10(4):1283-1292.

19. Zoccarato M, Gennuso M, Ottaviani S, et al. NMDAR encephalitis following post-herpes encephalitis. *Neurology.* 2017;88(16 Supplement 1).

20. Kataoka H, Sawa N, Tonomura Y, Ueno S. Early progression of brain atrophy in patients with anti-N-methyl-D - Aspartate receptor encephalitis. *Medicine (United States).* 2017;96(17):e6776.

21. Bashiri FA, Al-Rasheed AA, Hassan SM, et al. Auto-immune anti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis: three case reports. *Paediatr Int Child Health.* 2017;37(3):222-226.

22. Bastos C, Garzon E, Moreira CH, et al. Peculiar electrographic pattern associated with anti-NMDAr encephalitis. Case series report. *Epilepsy Currents.* 2013;13(SUPPL. 1):361-362.

23. Gastaldi M, Thouin A, Coutinho EP, Jacobson L, Irani S, Vincent AC. Comparison of antibody assays in anti-NMDAR encephalitis. *European Journal of Neurology.* 2016;23(SUPPL. 2):577.

24. Nosadini M, Sartori S, Toldo I, et al. Movement disorder and EEG patterns in anti-NMDAr antibodies encephalitis. *Clinical Neurophysiology.* 2013;124(11):e214.

25. Su H, Wang RF, Yu SY. Anti-N-methyl-D-aspartate receptor encephalitis: analysis of three cases. *Chinese Journal of Contemporary Neurology and Neurosurgery.* 2015;15(7):578-582.

26. Zandi MS, Paterson RW, Ellul MA, et al. Clinical relevance of serum antibodies to extracellular N-methyl-D-aspartate receptor epitopes. *J Neurol Neurosurg Psychiatry.* 2015;86(7):708-713.

27. Wright S, Hacohen Y, Cavalle A, et al. N-methyl-D-aspartate receptor (NMDA) antibody encephalitis mimicking autistic regression in infants. *Annals of Neurology.* 2015;78(SUPPL. 19):S80.

28. Sankhyan N, Singhi P, Suthar R, Saini AG, Sahu J. Cyclophosphamide in treatment resistant tumour negative pediatric NMDAR encephalitis. *European Journal of Paediatric Neurology.* 2015;19(SUPPL. 1):S60.

29. Aung T. A case report-importance of early treatment in anti-NMDA receptor encephalitis. *Epilepsy Currents.* 2015;15(SUPPL. 1):248.

30. Alexopoulos H, Akrivou S, Mastroyanni S, et al. Postherpes simplex encephalitis: a case series of viral-triggered autoimmunity, synaptic autoantibodies and response to therapy. *Therapeutic Advances in Neurological Disorders.* 2018;11.

31. Qin K, Wu W, Huang Y, et al. Anti-N-methyl-D-aspartate receptor(NMDAR) antibody encephalitis presents in atypical types and coexists with neuromyelitis optica spectrum disorder or neurosyphilis. *BMC Neurol.* 2017;17(1):1.

32. Qiu J, Helou J, Urriola N, et al. The expanding clinical phenotype of nmdar encephalitis. *Journal of Neurology, Neurosurgery and Psychiatry.* 2018;89(6):e31.

33. Kitada M, Suzuki H, Ichihashi J, Mitsui Y, Tanaka K, Kusunoki S. Dramatic improvement in two cases of anti-NMDA receptor encephalitis after immunomodulating therapy. *Clinical Neurology.* 2011;51(9):683-687.

34. Tuzun E, Coban A, Turkoglu R, Bilgic B, Hanatasi HA, Gurvit H. Anti-NMDA receptor encephalitis with cancer of unknown primary origin. *European Journal of Neurology.* 2015;22(SUPPL. 1):525.

35. Gaunt R, Mundada V, Muthugovindan D, Awadalla M. Acute behavioural change as the only presenting symptom of anti-N-methyl-D-aspartate receptor encephalitis relapse. *Developmental Medicine and Child Neurology.* 2017;59(Supplement 1):80.

36. Crowe BHA, Bamford A, Sivaporn A, et al. NMDA receptor antibody encephalitis associated movement disorder post HSV encephalitis with extensive acquired brain injury: A therapeutic challenge. *Developmental Medicine and Child Neurology.* 2014;56(SUPPL. 1):29.

37. Bektas O, Tanyel T, Aldemir B, Fitoz S, Ince E, Deda G. A different presentation of anti-N-methyl-D-aspartate receptor encephalitis: Anti-N-metyl-D-aspartate receptor encephalitis that developed after herpes encephalitis. *European Journal of Paediatric Neurology.* 2013;17(SUPPL. 1):S83-S84.

38. Iyer A, Griffiths M, Barborie A, Solomon T, Kneen R. NMDAR encephalitis with evidence of coexistant HSV infection proven on brain biopsy. *Developmental Medicine and Child Neurology.* 2014;56(SUPPL. 1):31.

39. Deiva K, Pera MC, Maurey H, et al. Sudden and isolated Broca's aphasia: a new clinical phenotype of anti NMDA receptor antibodies encephalitis in children. *Eur J Paediatr Neurol.* 2014;18(6):790-792.

40. Barros P, Brito H, Ferreira PC, et al. Resective surgery in the treatment of super-refractory partial status epilepticus secondary to NMDAR antibody encephalitis. *Eur J Paediatr Neurol.* 2014;18(3):449-452.

41. Lee LH, Lu CJ. Long-term and Strong Immunotherapy to Treat Anti-N-Methyl- D-Aspartate Receptor Encephalitis with Refractory Status Epilepticus. *Acta Neurol Taiwan.* 2016;25(3):99-103.

42. Tamma PD, Agwu AL, Hartman AL. Behavior outbursts, orofacial dyskinesias, and CSF pleocytosis in a healthy child. *Pediatrics.* 2011;128(1):e242-245.

43. Mitani T, Ohtsuka Y, Yamamoto K, et al. An 8-year-old boy with anti-NMDA receptor encephalitis, successfully treated with cyclophosphamide. *No To Hattatsu.* 2013;45(1):53-57.

44. Cai X, Zhou H, Xie Y, Yu D, Wang Z, Ren H. Anti- N -methyl- d -aspartate receptor encephalitis associated with acute Toxoplasma gondii infection. *Medicine (United States).* 2018;97(7):e9924.

45. Korenke C, Poggenburg I, Bien C, Marquardt I. Anti-N-methyl-d-aspartate-receptor-encephalitis. *Neuropediatrics.* 2013;44(2).

46. Elango N, Chandramouleeswaran V, Ramakrishnan V, Gobinathan S. NMDA receptor Ab encephalitis presenting with acute psychosis - A case report. *Annals of Indian Academy of Neurology.* 2016;19(6):S60.

47. Babiker MOE, Grattan R, MacLeod S, Dorris L, Zuberi SM. Chronic and relapsing paediatric anti-NMDAR encephalitis: Two cases and a literature review. *European Journal of Paediatric Neurology.* 2015;19(SUPPL. 1):S85.

48. Kevere L, Kramina S, Purvina S, et al. Anti-NMDA receptor autoimmune encephalitis in psychiatric practice. *European Neuropsychopharmacology.* 2015;25(SUPPL. 2):S225.

49. Rangseekajee P, Paholpak P, Kriengburapa K, Tiamkao S, Kasemsap N. Neuroleptic malignant syndrome and malignant catatonia as the manifestations of an anti-NMDAR encephalitis: A case report. *Asia-Pacific Psychiatry.* 2015;7(Supplement 1):28.

50. Ubod S, Bael V, Kimseng KJ. Anti- N-methyl-D-aspartate receptor encephalitis in a 15 year old male. *International Journal of Rheumatic Diseases.* 2016;19(Supplement 2):63-64.

51. Wang D, Wang S, Huang X, Wang Q. Heterotopic ossification following anti-NMDA receptor encephalitis: a case report. *BMC Neurol.* 2016;16(1):232.

52. Dasyam N, Varma R, Muthukrishnan A, Goldstein A. Diffuse cerebral hypometabolism with focal reduction in somatosensory and occipital cortical uptake on brain fdg pet in a case of anti NMDA receptor encephalitis. *Annals of Neurology.* 2014;76(SUPPL. 18):S182.

53. Nastase R, Petrescu A, Tiliscan C, et al. Anti-NMDA Receptor Encephalitis Associated with Benign Ovarian Teratoma - Case Report. *Journal of Gastrointestinal and Liver Diseases.* 2012;21(4):24.

54. Pereira F, Pedrosa S, Martins H, Dias C. Anti-NMDA limbic encephalitis: A case of secondary epilepsy. *Journal of Neurosurgical Anesthesiology.* 2016;28(2):S27.

55. Sousa S, Pita F, Carmona C, Guerreiro R. Kleine-Levin syndrome as a manifestation of anti-NMDAR encephalitis. *Journal of Neurology.* 2014;261(SUPPL. 1):S384.

56. Gutierrez-Zuniga R, Ruiz-Jimenez J, Vilchez-Carrillo RM, et al. NMDA autoimmune encephalitis triggered by a herpes simplex virus encephalitis: A case report. *European Journal of Neurology.* 2016;23(SUPPL. 2):578-579.

57. Shimoyama Y, Umegaki O, Agui T, Kadono N, Minami T. Anti-NMDA receptor encephalitis presenting as an acute psychotic episode misdiagnosed as dissociative disorder: a case report. *JA Clinical Reports.* 2016;2(1):22.

58. Fontao L, Alves I, Santos C. Overlapping demyelinating syndrome in an anti-NMDA encephalitis case. *European Journal of Neurology.* 2016;23(SUPPL. 2):577.

59. Liang CA, Showalter J, Tint H, Castillo B, Klein K, Bai Y. Multiple plasmapheresis procedures: Essential in treatment of anti-NMDAR encephalitis. *Transfusion.* 2016;56(Supplement 4):85A.

60. Wang X, Lai Y, Li P, Zhou K, Che G. Massive idiopathic spontaneous hemothorax complicating anti-N-methyl-d-aspartate receptor encephalitis: A case report. *Medicine (United States).* 2018;97(45):e13188.

61. Algra J, Xu Q, Fusco HN. Prolonged inpatient rehabilitation in a patient with severe N-methyl-D-aspartate receptor antibody encephalitis. A case report. *PM and R.* 2014;6(9 SUPPL. 1):S311.

62. Barrozo HG, Hernandez D. Anti-NMDA receptor encephalitis: An emerging diagnostic challenge. *Journal of the Neurological Sciences.* 2017;381(Supplement 1):530-531.

63. Fauzi NAM, Joseph JP, Zain NRM, Hashim H. A severe anti-NMDA-receptor encephalitis case with extensive cortical and white matter changes, cerebral atrophy and communicating hydrocephalus. *Proceedings of Singapore Healthcare.* 2017;26(1):58-61.

64. Salehi N, Yuan AK, Stevens G, Koshy R, Klein WF. A Case of Severe Anti-N-Methyl D-Aspartate (Anti-NMDA) Receptor Encephalitis with Refractory Autonomic Instability and Elevated Intracranial Pressure. *The American journal of case reports.* 2018;19:1216-1221.

65. Tachibana N, Shirakawa T, Ishii K, et al. Expression of Various Glutamate Receptors Including N-Methyl-D-Aspartate Receptor (NMDAR) in an Ovarian Teratoma Removed from a Young Woman with Anti-NMDAR Encephalitis. *Internal Medicine.* 2010;49(19):2167-2173.

66. Vansia P, Bisht S, Jaja G. Anti-NMDA receptor encephalitis associated with immature ovarian teratoma in a 22-year-old woman-an unusual case. *BJOG: An International Journal of Obstetrics and Gynaecology.* 2016;123(Supplement 2):98.

67. Amado-Rodriguez L, Ocampos-Martinez E, Fernandez R, et al. Neurological recovery after autoimmune encephalitis and titrated anti-N-methyl-D-aspartate-receptor antibody levels: A case report. *American Journal of Respiratory and Critical Care Medicine.* 2018;197(MeetingAbstracts).

68. Rehder D. Anti-NMDA receptor encephalitis. *Emergency Radiology.* 2016;23(6):592-593.

69. Grewal KS, Bhatia R, Singh N, Singh R, Dash D, Tripathi M. Confusional state in a pregnant woman: A case of NMDA receptor encephalitis during pregnancy. *Journal of Neuroimmunology.* 2018;325:29-31.

70. Anadani N, Jaggi S, Nakai R, Ricketti P, Feoli E. Co-existence or co-incidence? : NMDA-R encephalitis and brugada syndrome. *Annals of Neurology.* 2014;76(SUPPL. 18):S76.

71. Shahani L. Steroid Unresponsive Anti-NMDA Receptor Encephalitis During Pregnancy Successfully Treated With Plasmapheresis. *Journal of Neuropsychiatry and Clinical Neurosciences.* 2014;26(2):4.

72. Shahbeigi S, Ali Sepehry A, Oger J. Clinical manifestations of Anti-NMDAR encephalitis: Case series and practical recommendations for treatment. *Journal of Neuroimmunology.* 2014;275(1-2):39.

73. Kaneko K, Sato DK, Misu T, et al. Anti-NMDAR+/anti-MOG+ recurrent ADEM. *Multiple Sclerosis.* 2015;21(6):836.

74. O'Donnell L, Iyer P, Togher Z, et al. Seek and you will find: An unusual immune mediated encephalitis with multiple neuronal antibodies. *Neurology.* 2017;88(16 Supplement 1).

75. Li H, Guo YK, Cui YL, Peng T. Anti-N-methyl-D-aspartate receptor encephalitis: A case report. *Medicine (United States).* 2018;97(50):e13625.

76. Cesarini EN, Verzina A, Mancini A, et al. The role of EEG in the diagnosis of anti-Nmdar receptor encephalitis. *Epilepsia.* 2018;59(Supplement 3):S65.

77. Hegen H, Uprimny C, Grams A, et al. Bi-insular cortical involvement in anti-NMDA-receptor encephalitis - a case report. *BMC Neurol.* 2016;16:130.

78. Takahashi C, Hinson H, Bourdette D. Anti-NMDA receptor encephalitis with PSH: An under-recognized association with treatment implications? *Neurology.* 2013;80(1 MeetingAbstracts).

79. Yamamoto M, Kokubun N, Watanabe Y, Okabe R, Nakamura T, Hirata K. NMDA receptor encephalitis in the course of recurrent CNS demyelinating disorders: A case report. *Clinical Neurology.* 2013;53(5):345-350.

80. Bashir H, Kass J. Intrathecal NMDA receptor antibody reactivation due new ovarian teratoma in patient with previously resected ovarian teratoma for anti-NMDA receptor encephalitis. *Neurology.* 2017;88(16 Supplement 1).

81. Chourasia N, Watkins MW, Lankford JE, Kass JS, Kamdar A. An Infant Born to a Mother With Anti-N-Methyl-D-Aspartate Receptor Encephalitis. *Pediatric Neurology.* 2018;79:65-68.

82. Munoz ASK, Manahan MRP, Syki-Young MC. Anti-NMDAR encephalitis in a young woman with an ovarian teratoma. *BJOG: An International Journal of Obstetrics and Gynaecology.* 2015;122(SUPPL. 2):123.

83. Park J, Jho SH, Park YM, Kim HJ, Kim J. Anti-nmda receptor encephalitis: Initially presenting as Gerstmann syndrome. *Epilepsia.* 2018;59(Supplement 3):S107.

84. Hur J. Fever of Unknown Origin: An Unusual Presentation of Anti-N-Methyl-D-Aspartate Receptor Encephalitis. *Infect Chemother.* 2015;47(2):129-132.

85. Lineberry O, Patil A, Bailley K. A case report: 38-year-old female with anti-NMDA-receptor encephalitis without ovarian teratoma or occult malignancy. *Chest.* 2013;144(4 MEETING ABSTRACT).

86. Thomas AA, Dalmau J, Gresa-Arribas N, Fadul CE. Anti-NMDA receptor encephalitis: A patient with refractory illness after 25 months of intensive immunotherapy. *Neuro-Oncology.* 2012;14(SUPPL. 6).

87. Wagner J, Schwarz G, Puttinger G, et al. Anti-NMDA receptor encephalitis triggered by epilepsy surgery. *European Journal of Neurology.* 2018;25(Supplement 2):169.

88. Hung SKY, Viswanathan S, Arip M, Hiew FL, Puvanarajah S. A catastrophic case of anti NMDA receptor encephalitis with Japanese encephalitis, borrelia burgdorferi, bartonella henselae and herpes simplex virus co-infections. *Journal of the Neurological Sciences.* 2017;381(Supplement 1):906.

89. Rojc B, Podnar B, Graus F. A case of recurrent MOG antibody positive bilateral optic neuritis and anti-NMDAR encephalitis: Different biological evolution of the two associated antibodies. *Journal of Neuroimmunology.* 2019;328:86-88.

90. Zoccarato M, Zuliani L, Saddi MV, et al. AQP4-neuromyelitis optica following NMDAR-encephalitis: A case report. *Journal of the Neurological Sciences.* 2013;333(SUPPL. 1):e663.

91. Power S, Fahy RJ, Redmond J. NMDA encephalitis, a case study. *Irish Journal of Medical Science.* 2017;186(6 Supplement 1):S206.

92. Zhou J, Tan W, Tan SE, Hu J, Chen Z, Wang K. An unusual case of anti-MOG CNS demyelination with concomitant mild anti-NMDAR encephalitis. *Journal of Neuroimmunology.* 2018;320:107-110.

93. Guan HZ, Ren HT, Yang XZ, et al. Limbic Encephalitis Associated with Anti-gamma-aminobutyric Acid B Receptor Antibodies: A Case Series from China. *Chin Med J (Engl).* 2015;128(22):3023-3028.

94. Jeraiby M, Depince-Berger A, Bossy V, Antoine JC, Paul S. A case of anti-NMDA receptor encephalitis in a woman with a NMDA-R(+) small cell lung carcinoma (SCLC). *Clin Immunol.* 2016;166-167:96-99.

95. Chen MFC, Dougherty M, Dalmau J. Anti-NMDA-receptor encephalitis: Case report of persistent anti-NMDAR antibodies 10 years from initial undiagnosed presentation. *Neurology.* 2014;82(10 SUPPL. 1).

96. Kelleher E, McNamara P, Fitzmaurice B, et al. Prevalence rate of N-methyl-D-aspartate (NMDA) receptor antibodies in first episode psychosis. *European Psychiatry.* 2015;30(SUPPL. 1):1568.

97. Kukreti P, Garg A, Bhid L. Autoimmune encephalitis masquerading as psychosis: Diagnostic & therapeutic challenge. *Indian Journal of Psychiatry.* 2015;57(5 SUPPL. 1):S155-S156.

98. Mohammad SS, Sinclair K, Dale RC, Brilot F. Chorea and ballismus after herpes simplex 1 encephalitis associated with NMDAR antibodies. *Movement Disorders.* 2013;28(SUPPL. 1):S326.

99. Zhang W, Yan L, Jiao J. Repeated misdiagnosis of a relapsed atypical anti-NMDA receptor encephalitis without an associated ovarian teratoma. *Neurosci Lett.* 2017;638:135-138.

100. Orengo JP, Pekmezci M, Cree BA. Simultaneous serum aquaporin-4 antibody and CSF NMDA receptor antibody-positive encephalitis. *Neurol Neuroimmunol Neuroinflamm.* 2015;2(3):e101.

101. Berth S, Barreras P, Probasco JC, Solnes LB, Pardo CA, Ostrow LW. Nmdar subunit expression by atypical B cell lymphoma in a patient presenting with paraneoplastic encephalitis. *Annals of Neurology.* 2017;82(Supplement 21):S127.

102. Finke C, Mengel A, Pruss H, Stocker W, Meisel A, Ruprecht K. Anti-NMDAR encephalitis mimicking HaNDL syndrome. *Cephalalgia.* 2014;34(12):1012-1014.

103. Lab S. SIR - SCImago Institutional Rankings. Published 2019. Accessed 20 Aug 2019, 2019.